Biontech SE
BNTX99.850USD
+1.000+1.01%
Cierre 01/09, 16:00（ET）Cotizaciones retrasadas 15 min
24.01BCap. mercado
PérdidaP/E TTM
Más Datos de Biontech SE Compañía
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Información de Biontech SE
Símbolo de cotizaciónBNTX
Nombre de la empresaBiontech SE
Fecha de salida a bolsaOct 10, 2019
Director ejecutivoSahin (Ugur)
Número de empleados6772
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 10
DirecciónAn der Goldgrube 12
CiudadMAINZ
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísGermany
Código postal55131
Teléfono4949613190840
Sitio Webhttps://www.biontech.com/
Símbolo de cotizaciónBNTX
Fecha de salida a bolsaOct 10, 2019
Director ejecutivoSahin (Ugur)
Ejecutivos de Biontech SE
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Michael Motschmann
Mr. Michael Motschmann
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Michael Horowicz
Mr. Michael Horowicz
Director, Investor Relations
Director, Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Desglose de ingresos
Divisa: USDActualizado: mié., 12 de mar
Divisa: USDActualizado: mié., 12 de mar
FY2019
FY2018
FY2017
Por negocioUSD
Nombre
Ganancia
Proporción
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Estadísticas de accionistas
Actualizado: sáb., 15 de nov
Actualizado: sáb., 15 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Baillie Gifford & Co.
3.04%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
Otro
38.36%
Accionistas
Accionistas
Proporción
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Baillie Gifford & Co.
3.04%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
Otro
38.36%
Tipos de accionistas
Accionistas
Proporción
Corporation
59.74%
Investment Advisor
15.63%
Investment Advisor/Hedge Fund
3.83%
Individual Investor
2.11%
Research Firm
1.19%
Hedge Fund
1.05%
Sovereign Wealth Fund
0.63%
Bank and Trust
0.22%
Pension Fund
0.18%
Otro
15.43%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
774
54.93M
21.75%
-6.01M
2025Q3
808
54.84M
25.69%
-1.45M
2025Q2
821
56.21M
24.34%
+2.26M
2025Q1
832
54.17M
23.64%
-2.66M
2024Q4
855
52.85M
22.63%
+3.24M
2024Q3
827
49.68M
20.44%
+4.23M
2024Q2
801
45.24M
20.73%
+361.30K
2024Q1
817
44.34M
21.44%
-6.62M
2023Q4
879
44.00M
20.40%
+3.38M
2023Q3
904
40.73M
20.46%
-291.47K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
AT Impf GmbH
101.85M
40.33%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
15.89%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
7.88M
3.12%
-159.51K
-1.98%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.98M
1.97%
-2.00M
-28.65%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
4.83M
1.91%
+1.24M
+34.32%
Sep 30, 2025
Flossbach von Storch AG
4.23M
1.68%
-65.00
-0.00%
Sep 30, 2025
PRIMECAP Management Company
3.87M
1.53%
-130.70K
-3.27%
Sep 30, 2025
Dodge & Cox
3.65M
1.44%
+2.77M
+315.65%
Sep 30, 2025
Sahin (Ugur MD)
2.05M
0.81%
-724.50K
-26.11%
Mar 31, 2025
Pfizer Inc
1.66M
0.66%
-2.00M
-54.67%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Langar Global HealthTech ETF
4.06%
iShares Genomics Immunology and Healthcare ETF
3.6%
First Trust NYSE Arca Biotechnology Index Fund
3.42%
Global X Genomics & Biotechnology ETF
3.11%
WisdomTree BioRevolution Fund
2.74%
Franklin Genomic Advancements ETF
2.46%
VanEck Biotech ETF
2.38%
Virtus LifeSci Biotech Products ETF
1.58%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.01%
Ver más
Langar Global HealthTech ETF
Proporción4.06%
iShares Genomics Immunology and Healthcare ETF
Proporción3.6%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.42%
Global X Genomics & Biotechnology ETF
Proporción3.11%
WisdomTree BioRevolution Fund
Proporción2.74%
Franklin Genomic Advancements ETF
Proporción2.46%
VanEck Biotech ETF
Proporción2.38%
Virtus LifeSci Biotech Products ETF
Proporción1.58%
ProShares Ultra Nasdaq Biotechnology
Proporción1.02%
Invesco Nasdaq Biotechnology ETF
Proporción1.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Biontech SE?
Los cinco principales accionistas de Biontech SE son:
AT Impf GmbH posee 101.85M acciones, lo que representa el 40.33% del total de acciones.
Medine GmbH posee 40.13M acciones, lo que representa el 15.89% del total de acciones.
Baillie Gifford & Co. posee 7.88M acciones, lo que representa el 3.12% del total de acciones.
Fidelity Management & Research Company LLC posee 4.98M acciones, lo que representa el 1.97% del total de acciones.
T. Rowe Price Investment Management, Inc. posee 4.83M acciones, lo que representa el 1.91% del total de acciones.
AT Impf GmbH posee 101.85M acciones, lo que representa el 40.33% del total de acciones.
Medine GmbH posee 40.13M acciones, lo que representa el 15.89% del total de acciones.
Baillie Gifford & Co. posee 7.88M acciones, lo que representa el 3.12% del total de acciones.
Fidelity Management & Research Company LLC posee 4.98M acciones, lo que representa el 1.97% del total de acciones.
T. Rowe Price Investment Management, Inc. posee 4.83M acciones, lo que representa el 1.91% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Biontech SE?
Los tres principales tipos de accionista de Biontech SE son:
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
¿Cuántas instituciones poseen acciones de Biontech SE (BNTX)?
A fecha de 2025Q4, 774 instituciones poseen acciones de Biontech SE, con un valor de mercado combinado de aproximadamente 54.93M, lo que representa el 21.75% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -3.93%.
¿Cuál es la mayor fuente de ganancias de Biontech SE?
El FY2019, el segmento empresarial Collaboration Revenue generó la ganancia más alta para Biontech SE, ascendiendo a 84.43M y representando el 77.75% de la ganancia total.
